Trials / Completed
CompletedNCT03181984
Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 501 (actual)
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 14 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is to provide safety information of hemoporfin during the post-marketing period as required by China Food and Drug Administration (CFDA) regulations in order to identify any potential drug related treatment factors in the Chinese population, such as unknown/unexpected adverse reactions, the incidence of adverse reactions under the routine drug uses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hemoporfin | Hemoporfin mediated photodynamic therapy |
Timeline
- Start date
- 2017-08-31
- Primary completion
- 2023-04-19
- Completion
- 2023-04-19
- First posted
- 2017-06-09
- Last updated
- 2023-12-20
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03181984. Inclusion in this directory is not an endorsement.